Synedgen, Inc. - Award Notice
Type: Special Notice
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFOFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSEBARDA - ASPR / DAAPPO / BARDA DCMAWASHINGTON, DC, 20515, USA

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

PSC

HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT (AN13)
Timeline
    Description

    The Department of Health and Human Services (HHS) has awarded a federal contract to Synedgen, Inc. for the advance development of PAAG17G (DP), a high molecular weight glycopolymer designed as a medical countermeasure to mitigate mortality and morbidity following exposure to lethal ionizing radiation. This contract, valued at $16,937,463, emphasizes the government's commitment to enhancing public health safety in emergency situations, particularly in the context of biodefense and medical innovation. The project will be performed in Claremont, California, with the contract effective from September 26, 2024, and responses to the associated solicitation number BAA-23-100-SOL-00004 due by October 2, 2024. For further inquiries, interested parties may contact Jonathan Gonzalez, the Contracting Officer, at Jonathan.Gonzalez@hhs.gov or (202) 381-7248.

    Point(s) of Contact
    Jonathan Gonzalez, Contracting Officer
    (202) 381-7248
    Jonathan.Gonzalez@hhs.gov
    Joann Kambaja, Contract Specialist
    (202) 913-5470
    Joann.Kambaja@hhs.gov
    Files
    Title
    Posted
    The awarded contract number 75A50124C00047, effective from September 26, 2024, pertains to the advance development of PAAG17G (DP:MIIST305), a high molecular weight glycopolymer intended as a medical countermeasure against lethal ionizing radiation. The contract, valued at $16,937,463, was awarded to Synedgen, Inc. It falls under PSC 6505 and will be performed in the United States. The solicitation number associated with the award is BAA-23-100-SOL-00004, and responses are due by October 2, 2024. The contracting officer managing this procurement is Jonathan Gonzalez from the Department of Health and Human Services (HHS). The project focuses on developing a daily oral treatment designed to minimize mortality and morbidity resulting from radiation exposure, which underscores the government's emphasis on enhancing public health safety in emergency situations. This contract represents a strategic investment in biodefense and medical innovation to address potential radiological threats.
    Lifecycle
    Title
    Type
    Special Notice
    Similar Opportunities
    Radiation Dosimetry
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Biomedical Advanced Research and Development Authority (BARDA), is seeking proposals for the development of standardized radiation dosimetry guidelines for nonclinical models used in radiation research. The primary objective is to create harmonized dosimetry practices across BARDA's research portfolio, which is crucial for ensuring consistent and comparable data in medical countermeasures against various threats, including chemical, biological, radiological, and nuclear hazards. This five-year contract includes a two-year base period with three optional one-year extensions, and it requires comprehensive services such as irradiator assessments and the fabrication of phantoms for animal models. Interested vendors should submit their proposals, including detailed organizational information and past performance documentation, by the specified deadlines, with the estimated award date projected for the third quarter of fiscal year 2025. For further inquiries, contact Audrey Glover at audrey.glover@hhs.gov or Joann Kambaja at Joann.Kambaja@hhs.gov.
    Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority (BARDA), is soliciting proposals under the Broad Agency Announcement (BAA) BAA-23-100-SOL-00004 for advanced research and development of Medical Countermeasures (MCMs) aimed at addressing public health threats such as chemical, biological, radiological, and nuclear (CBRN) incidents, as well as emerging infectious diseases and pandemic influenza. The initiative seeks to foster public-private partnerships to enhance the development and responsiveness of life-saving MCMs, emphasizing the importance of technological maturity, regulatory compliance, and manufacturing standards in the evaluation process. This opportunity is critical for strengthening national health security and improving preparedness for future public health emergencies, with an open submission period running until September 25, 2028, at 4:30 PM Eastern Time. Interested parties can direct inquiries to BARDA-BAA@hhs.gov for further information.
    2026 NIAID DMID Omnibus Broad Agency Announcement
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), is soliciting proposals for the 2026 DMID Omnibus Broad Agency Announcement (BAA) aimed at advancing research and development of medical countermeasures against antimicrobial-resistant pathogens and viruses with pandemic potential. The BAA encompasses two primary research areas: the development of therapeutics, vaccines, and diagnostics for antimicrobial-resistant (AMR) bacterial and fungal pathogens, and the creation of Direct Acting Antivirals (DAA) targeting viruses of pandemic potential. This initiative is critical for addressing public health challenges related to infectious diseases, with an estimated funding of $28.5 million available for awards in fiscal year 2026. Proposals for Research Area 001 are due by February 21, 2025, while those for Research Area 002 must be submitted by January 21, 2025. Interested parties can contact Swee L. Teo at teosl@niaid.nih.gov or Brian Madgey at brian.madgey@nih.gov for further information.
    BARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Office of Biomedical Advanced Research and Development Authority (BARDA), is soliciting proposals under the Easy Broad Agency Announcement (EZ-BAA) BAA-22-100-SOL-00003, which focuses on innovative medical countermeasures (MCMs) to enhance public health preparedness against various threats, including infectious diseases and chemical agents. The initiative invites submissions across multiple Areas of Interest (AOIs), including but not limited to vaccine innovations, diagnostic technologies, and therapeutic solutions for acute radiation syndrome and chemical threats. This opportunity is critical for advancing biomedical research and developing effective responses to health emergencies, with multiple awards anticipated based on scientific merit and funding availability. Interested parties must register on SAM.gov and submit their abstracts by specified deadlines, with key submission dates ranging from March 15, 2024, to May 31, 2024, depending on the AOI. For further inquiries, respondents can contact Aarati Singal or Lara Emmons at DRIVeAcquisitions@hhs.gov.
    FY24 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science Award Notice
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Food and Drug Administration (FDA), has announced the FY24 Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science. This opportunity aims to support innovative research projects that enhance regulatory science, with a focus on health, medical, and biotechnology advancements. The awarded contracts, totaling over $24 million, cover a range of critical topics including drug safety, gene therapy, and methodologies for assessing pediatric opioid exposure, reflecting the federal government's commitment to fostering research initiatives that improve healthcare delivery and regulatory processes. Interested parties can contact Ian Weiss at Ian.Weiss@fda.hhs.gov or by phone at 301-796-5728 for further information.
    Public Health Industrial Base Capabilities and Capacities: Anti-Microbials
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services (HHS) is seeking industry partners to provide information regarding domestic production capabilities related to anti-microbials under the Defense Production Act Title III Program. The objective of this Request for Information (RFI) is to identify gaps in the Public Health Industrial Base (PHIB) and enhance national defense resources by focusing on the production of essential medicines and medical countermeasures sourced domestically. Respondents are encouraged to share insights on their manufacturing processes, regulatory compliance, and infrastructure, as well as past supply chain disruptions and investment needs, with responses due by January 6, 2025, at 10 AM ET. Interested parties should submit their responses to Chris Newell at IBMSC-Submissions@hhs.gov.
    BROAD AGENCY ANNOUNCEMENT (BAA) RESEARCH AND DEVELOPMENT IN SUPPORT OF THE JOINT PROGRAM EXECUTIVE OFFICE FOR CHEMICAL, BIOLOGICAL, RADIOLOGICAL AND NUCLEAR DEFENSE (JPEO-CBRND), JPM MEDICAL AND JPL EB
    Active
    Dept Of Defense
    Solicitation DEPT OF DEFENSE is seeking research and development services in support of the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB. The service being procured is for the identification of the best available science in the areas of research interest, including novel solutions and improved methods for developing medical countermeasures. The government is specifically interested in enabling technologies, life cycle bioinformatics, and improved logistics tracking. The procurement notice is available on SAM.gov and the JPEO-CBD website. Potential offerors are encouraged to communicate with the JPMO technical contacts for proposal ideas. For any questions or inquiries, contact usarmy.detrick.mcs.mbx.baa@mail.mil.
    FY25 Bulk Pharma Buy (Materiel)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (ASPR), is seeking information from vendors regarding the procurement of pharmaceuticals for the Strategic National Stockpile (SNS) under the FY25 Bulk Pharma Buy initiative. The RFI aims to gather details on vendors' capabilities to supply FDA-approved pharmaceuticals, including Amoxicillin, Ciprofloxacin, and Clindamycin, which are critical for public health emergencies. This procurement is vital for ensuring rapid access to life-saving medical supplies during biological, chemical, and radiological threats, as well as natural disasters. Interested vendors must submit their responses electronically by January 8, 2025, and can direct inquiries to Terri Reed at terri.reed@hhs.gov.
    Ongoing Monoclonal Antibodies and Plasmids Services through GENSCRIPT
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), intends to negotiate a sole-source contract with GenScript USA Inc. for ongoing monoclonal antibodies and plasmids services. The procurement aims to support the NIAID Laboratory of Immunogenetics (LIG) in advancing research on human B cells and the isolation of monoclonal antibodies, which are critical for developing new vaccine candidates against influenza. This contract is a continuation of existing services that require continuity for accurate comparison of results, and interested parties may submit capability statements via the NIAID electronic Simplified Acquisition Submission System (eSASS) by January 3, 2025, at 5:00 PM ET. For further inquiries, contact Dana Monroe at dana.monroe@nih.gov or call 406-375-9814.
    Hybridoma Development Studies and Antibody Production
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency (DHA), is soliciting proposals for a contract focused on hybridoma development studies and antibody production for the Division of Virology at the USAMRIID. The objective of this procurement is to secure severable, non-personal services that will support research in molecular virology, cell biology, immunology, and related fields. This work is critical for advancing understanding in viral virulence factors and strain diversity, which are essential for public health and military readiness. Interested small businesses are encouraged to reach out to Shelley Wallace at shelley.a.wallace2.civ@health.mil or 301-619-1352, or Emily OHara at emily.k.ohara.civ@health.mil or 301-619-9599 for further details regarding the solicitation.